Join this webinar with our invited speaker Paula Tabares, PhD

“Monitoring Circulating Plasma Cells in routine diagnostics in Multiple Myeloma”

Do you know that the evaluation of Circulating Tumor Plasma Cells (CTPC) can have an impact on patient management?

Next Generation Flow Cytometry (NGFC) plays an important role in diagnostics, providing a highly sensitive method to generate reliable data of clinical relevance in different plasma cell (PC) dyscrasias.

In the recent years, NGFC has been successfully used for diagnosis and monitoring in multiple myeloma (MM), a hematological malignancy characterized by the growth of clonal plasma cells in the bone marrow. Large cohort studied with NGFC, also in comparison with other detection methods, have highlighted its impact in predicting patient survival. Moreover, recent studies showed the presence of MM tumor malignant cells in peripheral blood, which can be detected and quantified by using NGFC, providing additional prognostic information.

In this webinar, Dr. Paula Tabares will describe the flow-based method for detection of CTPC in peripheral blood and the benefit of assessing CTPC in the clinical routine.

Paula Tabares, PhD
Scientist in Research and Diagnostics
Interdisciplinary Center for Clinical Research Laboratory
Department of Medicine II, University Hospital of Würzburg, Germany

• Bachelor´s degree in Industrial Chemistry (2004). Universidad Tecnológica de Pereira, Colombia.
• Doctoral degree in natural sciences (2011). University of Würzburg, Germany.
• From 2012 to 2017 Dr. Tabares worked as a researcher at the group of Prof. Dr. Thomas Hünig at the University of Würzburg, where she studied the effects of the CD28 superagonist TGN1412  on regulatory T-cells and contributed to the return of TGN1412 therapy to clinical development for the treatment of rheumatoid arthritis.
• In 2018, she joined the research group of Prof. Dr. Andreas Beilhack, where she established flow cytometry based MRD and CTPC methods to evaluate tumor cells in patients with multiple myeloma (MM), following the EuroFlow™ guidelines. The method to detect circulating plasma cells is now for the first time incorporated into the clinical routine to monitor MM patients in Germany.

In her current research, she investigates the phenotypic profile of cancer cells, immune cells and cells of the tumor microenvironment in patients with multiple myeloma and solid cancers utilizing next generation flow cytometry.